These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38810201)

  • 1. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Manesh A; Varghese GM; Paterson DL
    N Engl J Med; 2024 May; 390(20):1938. PubMed ID: 38810201
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Lanini S; Cai T; Tascini C
    N Engl J Med; 2024 May; 390(20):1937. PubMed ID: 38810199
    [No Abstract]   [Full Text] [Related]  

  • 3. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    van Os W; Zeitlinger M
    N Engl J Med; 2024 May; 390(20):1937-1938. PubMed ID: 38810200
    [No Abstract]   [Full Text] [Related]  

  • 4. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. Reply.
    Wagenlehner FM; McGovern PC; Moeck G
    N Engl J Med; 2024 May; 390(20):1938-1939. PubMed ID: 38810202
    [No Abstract]   [Full Text] [Related]  

  • 5. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Wagenlehner FM; Gasink LB; McGovern PC; Moeck G; McLeroth P; Dorr M; Dane A; Henkel T;
    N Engl J Med; 2024 Feb; 390(7):611-622. PubMed ID: 38354140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
    Moeck G; Gasink LB; Mendes RE; Woosley LN; Dorr M; Chen H; Wagenlehner FM; Henkel T; McGovern PC
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0023624. PubMed ID: 38780262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?
    Bassetti M; Giacobbe DR
    Med; 2024 May; 5(5):380-382. PubMed ID: 38733970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d.
    Granwehr B
    Ann Intern Med; 2024 Jun; 177(6):JC67. PubMed ID: 38830218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime/enmetazobactam (Exblifep) for complicated urinary tract infections.
    Med Lett Drugs Ther; 2024 Jul; 66(1707):117-118. PubMed ID: 39008106
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
    Lasko MJ; Nicolau DP; Asempa TE
    J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cefepime (maxipime) in the treatment of severe urinary tract infection].
    Derevianko II
    Antibiot Khimioter; 2003; 48(7):24-8. PubMed ID: 14628575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug utilization study of two generic antibiotics in a tertiary hospital in Bogotá.
    López JJ; Cortázar Y; Acosta Á; Vargas-Peláez CM; Rossi F
    Biomedica; 2018 Sep; 38(3):398-406. PubMed ID: 30335245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
    Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dosage cefepime as treatment for serious bacterial infections.
    Giamarellou H
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():123-32. PubMed ID: 8150755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.
    Gentry LO; Rodriguez-Gomez G
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2371-4. PubMed ID: 1804010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime/Enmetazobactam for Complicated Urinary Tract Infections.
    Advani SD; Claeys K
    JAMA; 2022 Oct; 328(13):1299-1301. PubMed ID: 36194235
    [No Abstract]   [Full Text] [Related]  

  • 17. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
    Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
    JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms.
    Chiu CC; Lin TC; Wu RX; Yang YS; Hsiao PJ; Lee Y; Lin JC; Chang FY
    J Microbiol Immunol Infect; 2017 Dec; 50(6):879-885. PubMed ID: 28087318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.